Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sterns

<< Previous

Bullboard Posts

Next >>

Post by Doccoleon Jun 03, 2021 12:48pm

229 Views

Post# 33319517

Sterns

Christina was listed at the bottom of the article. Is sterns out? Not that they did anything for the stock price.

let's get this thing going North now! I would love to fantasize about potential- but here is the thing....This is a stock that hasn't moved much and when it has, management has pulled the rug out from under it. We need momentum and we need to get this on a senior exchange with momentum!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China